Yoshio Ogino

USPTO Granted Patents = 21 (Patent Applications = 3)

CIPO Patents = 2

EPO Patents = 8 (Patent Applications = 2)

Average Co-Inventor Count = 5.2

ph-index = 4

Forward Citations = 106(Granted Patents)

Location History:

Tokyo, JP (1995)
Tsukuba, JP (2005 - 2019)
Ibaraki, JP (2010 - 2023)

Company Filing History:

10 out of 237

Banyu Pharmaceutical Co. Ltd

Taiho Pharmaceutical Company Limited

patents

4. 2 out of 2,405

Merck Sharp + Dohme Corp.

patents

5. 1 out of 1

Nihon Kogden Corporation

patent

where one patent can have more than one assignee

Years Active: 1995-2023

Loading Chart...

21 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11786534 - Substituted pyrrolo[2,3-d]pyrimidines as EGFR inhibitors (2023-10-17),

2. 11634395 - Sulfonamide compound or salt thereof (2023-04-25),

3. 10889555 - Sulfonamide compound or salt thereof (2021-01-12),

4. 10370372 - Fused pyrimidine compound or salt thereof (2019-08-06),

5. 9145414 - 1,2,4-triazine-6-carboxamide derivative (2015-09-29),

6. 8614221 - Inhibitors of Akt activity (2013-12-24),

7. 8536193 - Inhibitors of AKT activity (2013-09-17),

8. 8207169 - Substituted [1,2,4]triazolo[4',3′:1,6]pyrido[2,3-b]pyrazines of the formula D (2012-06-26),

9. 7994331 - Heterocycle-substituted benzimidazole derivative (2011-08-09),

10. 7932394 - Aryloxy-substituted benzimidazole derivatives (2011-04-26),

11. 7803807 - Benzimidazole derivatives (2010-09-28),

12. 7799820 - 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions (2010-09-21),

13. 7728025 - 2-heteroaryl-substituted benzimidazole derivative (2010-06-01),

14. 7691860 - Sulfonamide derivatives (2010-04-06),

15. 7687514 - Benzimidazole derivatives (2010-03-30),

Title: The Innovations of Yoshio Ogino: Pioneering Research in EGFR Inhibition

Introduction: Yoshio Ogino, a prominent inventor based in Tsukuba, Japan, has made significant contributions to the field of pharmaceutical innovations. With a remarkable portfolio of 20 patents, he has been instrumental in the development of novel compounds aimed at inhibiting critical biological pathways. His work reflects a dedication to advancing medical science and improving therapeutic options for patients.

Latest Patents: Among his latest innovations, Ogino has developed compounds such as substituted pyrrolo[2,3-d]pyrimidines, specifically targeted as EGFR inhibitors. This invention provides a new compound for inhibiting EGFR or one of its pharmaceutically acceptable salts. Additionally, Ogino has created a novel sulfonamide compound known for its ribonucleotide reductase inhibitory activity, along with a pharmaceutical composition that includes this active ingredient. These compounds are represented by specific general formulas that detail their chemical structures, indicating Ogino’s meticulous attention to scientific detail.

Career Highlights: Yoshio Ogino has worked with esteemed companies in the pharmaceutical industry, including Banyu Pharmaceutical Co. Ltd and MSD K.K. His experience at these organizations has allowed him to engage in innovative research and development projects that have led to numerous patents aimed at addressing unmet medical needs.

Collaborations: Throughout his career, Ogino has collaborated with fellow researchers, including Norikazu Otake and Kenji Matsuda. These partnerships have enabled the pooling of expertise and resources, further fostering the environment of innovation necessary for breakthrough discoveries.

Conclusion: Yoshio Ogino's contributions to the field of pharmaceuticals exemplify the impact of dedicated inventors on medical advancements. With a strong focus on EGFR inhibition and other critical biological targets, Ogino's innovations are paving the way for new therapies that can significantly benefit patients. As he continues his work, the future appears bright for the ongoing developments emerging from his research endeavors.

This text is generated by artificial intelligence and may not be accurate.